December 1, 2014 Pfizer Inc. today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. “NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines …
